奥浦迈的前世今生：营收2.72亿行业排名28，净利润4905.68万行业排名18

Core Viewpoint - Aopumai, a leading company in the cell culture products and services sector in China, has shown significant growth potential despite its current lower ranking in revenue and profit compared to industry leaders [1][2]. Group 1: Company Overview - Aopumai was established on November 27, 2013, and was listed on the Shanghai Stock Exchange on September 2, 2022, with its headquarters in Shanghai [1]. - The company operates in the pharmaceutical and biotechnology sector, specifically in the bioproducts category, and has a comprehensive industry chain and technological research advantages [1]. Group 2: Financial Performance - For Q3 2025, Aopumai reported revenue of 272 million yuan, ranking 28th out of 34 in the industry, significantly lower than the top competitors [2]. - The revenue composition includes product revenue of 155 million yuan (87.34%), service revenue of 22.27 million yuan (12.53%), and other revenue of 0.233 million yuan (0.13%) [2]. - The net profit for the same period was 49.06 million yuan, ranking 18th in the industry, again trailing behind leading companies [2]. Group 3: Financial Ratios - Aopumai's debt-to-asset ratio stood at 7.59% in Q3 2025, slightly up from 7.00% year-on-year, but well below the industry average of 26.88%, indicating strong solvency [3]. - The gross profit margin was reported at 54.57%, down from 57.45% year-on-year and below the industry average of 70.17%, suggesting room for improvement in profitability [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 14.63% to 3,682, with an average holding of 30,800 shares, up 27.96% [5]. - Notable changes among the top ten circulating shareholders include increases in holdings by several funds, indicating growing investor interest [5]. Group 5: Future Outlook - Aopumai is expected to see revenue growth in the coming years, with projected revenues of 379 million yuan, 473 million yuan, and 586 million yuan for 2025, 2026, and 2027, respectively [5]. - The net profit forecasts for the same years are 87 million yuan, 107 million yuan, and 134 million yuan, reflecting a positive growth trajectory [5].